Twist Bioscience Corp stock (US90130A1016): shares steady after Q2 FY2026 results on Nasdaq

Twist Bioscience shares on Nasdaq traded broadly stable in the first session of June as investors continued to digest the synthetic DNA maker’s fiscal Q2 2026 results and outlook released in early May.

Twist Bioscience shares on the Nasdaq in the United States started the week with relatively calm trading as investors continued to evaluate the company’s latest quarterly figures and guidance following its fiscal second quarter 2026 earnings release filed in early May, which covered the period ended 03/31/2026, according to the company’s investor relations materials. While intraday moves on Nasdaq were modest in early U.S. trading on 06/01/2026, the stock remained in focus for biotechnology investors who follow synthetic DNA and genomics tools providers as part of the wider U.S. life sciences ecosystem.

In that fiscal Q2 2026 update, Twist Bioscience presented revenue and loss figures for the March quarter along with commentary on demand trends for its synthetic biology, next-generation sequencing (NGS) tools and biopharma segments, as well as updated expectations for the full 2026 fiscal year, according to the earnings documentation made available via its investor relations website and regulatory filings. The company also discussed progress on operational efficiency measures and cash burn, which remain key points for U.S.-listed, high-growth life sciences companies on exchanges such as Nasdaq where investors monitor progress toward long-term profitability.

The U.S. listing on Nasdaq under the ticker TWST anchors Twist Bioscience firmly in the American biotechnology capital markets, where the stock trades in U.S. dollars and is followed by U.S.-based and global healthcare specialists. The company’s financial reports are filed with the U.S. Securities and Exchange Commission, and its quarterly earnings releases are disseminated via its corporate website and established newswire channels, providing detailed figures on revenue by segment, operating expenses and net loss for each fiscal period. For European retail investors, the stock is also accessible in Germany via platforms such as Tradegate, where it trades in euros in addition to its primary U.S. dollar listing.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Twist Bioscience Corp
• Sector/industry: Biotechnology tools and synthetic DNA
• Headquarters/country: South San Francisco, United States
• Core markets: North America, Europe and Asia-Pacific genomics customers
• Key revenue drivers: Synthetic DNA products, NGS tools and biopharma collaborations
• Home exchange/listing venue: Nasdaq (TWST)
• Trading currency: USD

Twist Bioscience Corp: core business model

Twist Bioscience focuses on manufacturing high-throughput synthetic DNA and related genomics tools that it sells to research, biopharma and industrial customers, with revenue primarily generated from catalog and custom DNA products, NGS tools and partnerships that leverage its DNA synthesis platform in drug discovery, diagnostics and other applications.

What banks and research houses say about Twist Bioscience Corp

No verified analyst coverage was identified at the time of publication.

Conclusion

Twist Bioscience remains in focus on the Nasdaq after its fiscal Q2 2026 earnings report and related updates on revenue growth, operating performance and cash usage, even though trading on 06/01/2026 was relatively subdued compared with more volatile sessions around prior earnings events. With a business centered on synthetic DNA and genomics tools, the company continues to operate in a specialist segment of the U.S. biotechnology market that attracts investors who track innovation in research and biopharma workflows rather than near-term profitability alone. The combination of its listed status in the United States, access for European investors through German trading venues and ongoing newsflow around quarterly results and partnerships means the stock is likely to stay on watchlists for those following the synthetic biology and genomics tools space.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.